Andrew Grethlein
Chief Operating Officer chez GERON CORPORATION
Fortune : 7 481 $ au 31/03/2024
Profil
Andrew J.
Grethlein is currently the Chief Operating Officer & Executive Vice President at Geron Corp.
He previously worked as the Senior Director-South San Francisco Pharmaceutical at Elan Corp.
Plc from 1997 to 2003, Manager-Biologics Development & Manufacturing at Athena Neurosciences LLC from 1995 to 1997, Senior Vice President-Pharmaceutical Operations at Tercica, Inc. from 2003 to 2008, Senior Vice President-Hematology at Ipsen SA from 2008 to 2010, and Chief Operating Officer & Executive Vice President at Inspiration Biopharmaceuticals, Inc. from 2010 to 2012.
He also held a position as Principal at Ipsen International GmbH.
Dr. Grethlein holds a graduate and doctorate degree from Michigan State University, an undergraduate degree from Bates College, and an undergraduate degree from Bard College at Simon's Rock.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
GERON CORPORATION
0,00% | 01/03/2024 | 2 267 ( 0,00% ) | 7 481 $ | 31/03/2024 |
Postes actifs de Andrew Grethlein
| Sociétés | Poste | Début |
|---|---|---|
| GERON CORPORATION | Chief Operating Officer | 30/01/2019 |
Anciens postes connus de Andrew Grethlein
| Sociétés | Poste | Fin |
|---|---|---|
Inspiration Biopharmaceuticals, Inc.
 Inspiration Biopharmaceuticals, Inc. Medical SpecialtiesHealth Technology Inspiration Biopharmaceuticals, Inc. produces intravenous recombinant therapies and develops non-invasive applications. It offers its products for the hemophilia community. The company was founded by Scott Donnelly Martin and John Read Taylor, Jr. on April 28, 2006 and is headquartered in Boston, MA. | Chief Operating Officer | 01/09/2012 |
| IPSEN | Corporate Officer/Principal | 01/01/2010 |
Tercica, Inc.
 Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Corporate Officer/Principal | - |
Elan Corp. Plc
 Elan Corp. Plc Pharmaceuticals: MajorHealth Technology Elan Corp. Plc is a neuroscience focused biotechnology company. The company engages in research, development, and commercial activities for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease and autoimmune diseases, including multiple sclerosis. It was founded in December 1969 and is headquartered in Dublin, Ireland. | Corporate Officer/Principal | 01/01/2003 |
Athena Neurosciences LLC
 Athena Neurosciences LLC Miscellaneous Commercial ServicesCommercial Services Athena Neurosciences LLC operates as a research-based pharmaceutical company committed to the field of neurology. It develops therapeutic and diagnostic products. The company was founded by David Rowley-Jones, Larry C. Fritz, and Larry A. Bock in 1986 and is headquartered in Allegan, MI. | Corporate Officer/Principal | 01/01/1997 |
Formation de Andrew Grethlein
| Michigan State University | Doctorate Degree |
| Bates College | Undergraduate Degree |
| Bard College at Simon's Rock | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| GERON CORPORATION | Health Technology |
| IPSEN | Health Technology |
| Entreprise privées | 5 |
|---|---|
Elan Corp. Plc
Elan Corp. Plc Pharmaceuticals: MajorHealth Technology Elan Corp. Plc is a neuroscience focused biotechnology company. The company engages in research, development, and commercial activities for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease and autoimmune diseases, including multiple sclerosis. It was founded in December 1969 and is headquartered in Dublin, Ireland. | Health Technology |
Athena Neurosciences LLC
Athena Neurosciences LLC Miscellaneous Commercial ServicesCommercial Services Athena Neurosciences LLC operates as a research-based pharmaceutical company committed to the field of neurology. It develops therapeutic and diagnostic products. The company was founded by David Rowley-Jones, Larry C. Fritz, and Larry A. Bock in 1986 and is headquartered in Allegan, MI. | Commercial Services |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Health Technology |
Inspiration Biopharmaceuticals, Inc.
Inspiration Biopharmaceuticals, Inc. Medical SpecialtiesHealth Technology Inspiration Biopharmaceuticals, Inc. produces intravenous recombinant therapies and develops non-invasive applications. It offers its products for the hemophilia community. The company was founded by Scott Donnelly Martin and John Read Taylor, Jr. on April 28, 2006 and is headquartered in Boston, MA. | Health Technology |
Ipsen International GmbH
 Ipsen International GmbH Industrial MachineryProducer Manufacturing Ipsen International GmbH manufactures and distributes furnaces and plant systems. Its products include sealed quench furnaces; chamber and multi-purpose chamber furnaces; horizontal and vertical furnaces; EcoFire system; HydroNit Sensor; HybridCarb; and EndoSave system. The firm also provides software processes such as Carb-o-Prof 4.0, AutoMag, Vacu-Prof, and Conti-Control. The company was founded by Harold Ipsen in 1957 and is headquartered in Kleve, Germany. | Producer Manufacturing |
